Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Pittsburgh
Hummingbird Bioscience
Bristol-Myers Squibb
NRG Oncology
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Oscotec Inc.
Shanghai Miracogen Inc.
Eye & ENT Hospital of Fudan University
Mayo Clinic
Rakuten Medical, Inc.
Memgen, Inc.
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Akeso
MediLink Therapeutics (Suzhou) Co., Ltd.
Sun Yat-sen University
Sun Yat-sen University
Hospital of Stomatology, Wuhan University
Shanghai Jiao Tong University School of Medicine
Shanghai Jiao Tong University School of Medicine
Beijing Tongren Hospital
McGill University Health Centre/Research Institute of the McGill University Health Centre
Nanfang Hospital, Southern Medical University
Affiliated Cancer Hospital & Institute of Guangzhou Medical University